Navigation Links
Omnitura Therapeutics Announces Private Placement Financing
Date:1/29/2009

Company will proceed with clinical trials of first-in-class multivalent therapies for cancer

REDWOOD SHORES, Calif., Jan. 29 /PRNewswire/ -- Omnitura Therapeutics Inc. ("Omnitura") announced today that it has entered into a $24 million private placement agreement with multiple closings. Under the terms of this financing, investments will be made in three tranches: $8 million before March 31, 2009, $8 million before December 31, 2009 and $8 million before December 31, 2010. "We anticipate that these funds will cover Omnitura's operations for three years and enable us to proceed with Phase I and Phase II clinical development of Aneustat(TM), our lead multivalent cancer therapy," said Jeff Dao, President & COO of Omnitura. "In addition to our clinical development program, these funds will also enable us to further cultivate strategic alliances and implement the next steps of our comprehensive financing plans," said Mr. Dao.

Aneustat(TM) represents a first-in-class multifunctional multitargeted (MFMT(TM)) therapy, specifically designed to address the heterogeneous nature of cancer. Omnitura has exclusive worldwide rights to Aneustat(TM) under a license agreement with Genyous Biomed International, Inc.

About Omnitura Therapeutics Inc. and MFMT(TM) Therapies

Omnitura Therapeutics Inc., www.omnitura.com founded in 2001, is a bio-pharmaceutical company that develops and facilitates the marketing of a new class of multivalent drugs for the treatment of cancer. Our mission is to commercialize Multifunctional Multitargeted ("MFMT(TM)") oncology drugs. MFMT(TM) drugs possess multiple therapeutic functions and act upon multiple biological targets to treat complex chronic diseases, including cancer.

Omnitura's MFMT(TM) drug candidates, acquired via an exclusive worldwide license and joint development arrangement with Genyous Biomed In
'/>"/>

SOURCE Omnitura Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... PA (PRWEB) January 15, 2014 The Pittcon ... publisher of Food Safety Tech , an e-Journal and ... signed an agreement for the second year for the co-location ... Pittcon 2014. The partnership provides that the registration fee to ...
(Date:1/15/2014)... Westlake Village, Calif. (PRWEB) January 15, 2014 ... cancer treatment and management through the genomic analysis of ... will offer Therapy Finder™, a web-based cancer decision support ... a reporting option with Cynvenio’s ClearID™ genomic test, Therapy ...
(Date:1/15/2014)... January 15, 2014 This webinar will ... and clinical safety assessment in biosimilars. , Regulatory frameworks ... biosimilar drug development, however the complex nature of biopharmaceuticals ... safety and efficacy extremely challenging. Based on the specific ...
(Date:1/15/2014)... Two champions of science, technology, engineering, ... an annual competition for middle and high school students ... STEM study. The competition presents students with real-world problems ... Aptitude, Mathematics, and Sciences is a program administered ...
Breaking Biology Technology:Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5
... , The statement below is from Pete Nicholas, Chairman ... employees and its Board of Directors. , , ... remarkably broad spectrum of issues. Foremost among them was his long and ... , He was a tireless advocate for patients, rights and for ...
... , , , ... molecular testing solutions, announced today that the company has been invited ... Conference, which is being held from September 9-11, 2009 at the ... Kureshy, CEO & President will provide an overview of the company ...
... NEW YORK, Aug. 26 /PRNewswire-Asia-FirstCall/ -- American Oriental,Bioengineering, ... or "AOBO"), a pharmaceutical,company dedicated to improving health ... range of prescription and over the counter ("OTC"),products, ... have been included in,China,s Essential Drug List ("EDL"). ...
Cached Biology Technology:Boston Scientific Statement on the Passing of Senator Edward Kennedy 2AOBO's Products Included in China's Essential Drug List 2
(Date:4/17/2014)... In the most densely forested and most densely ... centuries of human needs, values and practices. Disturbances associated ... for agriculture and development, have set the stage for ... Service study reports. , The report Five anthropogenic ... needs in the Northern United States was ...
(Date:4/17/2014)... development of stem cell therapies to cure a variety ... cell populations based on cell surface markers. Researchers from ... that is highly expressed in a type of stem ... describe in an article in BioResearch Open Access ... publishers. The article is available free on the ...
(Date:4/17/2014)... detection cartridge developed at Sandia National Laboratories and recently ... faster and cheaper. , Bacillus anthracis , ... soils all over the world and can cause serious, ... The bacteria can survive in harsh conditions for decades. ... occur through skin contact, inhalation of spores or eating ...
Breaking Biology News(10 mins):Five anthropogenic factors that will radically alter northern forests in 50 years 2Five anthropogenic factors that will radically alter northern forests in 50 years 3Pocket-sized anthrax detector aids global agriculture 2Pocket-sized anthrax detector aids global agriculture 3
... million, five-year federal grant to The Children,s Hospital of ... novel approach in treating HIV infection---a unique class of ... effects in AIDS. Unlike many current HIV ... being studied cross into the brain, where HIV, the ...
... Targets and Cancer Therapeutics is the location to hear ... conference brings together delegates from all over the world ... the impact of new discoveries in molecular and cell ... of the conference, the program schedule is available online ...
... out in a crowd is better than blending in, ... colony where fights between nest-mates determine social status. ... Michigan researchers published online this week in the journal ... to wear a nametag advertising your identity," said graduate ...
Cached Biology News:NeuroAIDS is target of federal grant to Children's Hospital 2NeuroAIDS is target of federal grant to Children's Hospital 3NeuroAIDS is target of federal grant to Children's Hospital 4Being a standout has its benefits, study shows 2
... The RapidPlate 96/384 workstation offers precise ... highly scalable format. Utilizing 100ul and 200ul ... head delivers excellent accuracy and precision across ... position rotary deck includes two positions that ...
... you reduce the chance of error. Thats ... Developed using Beckman Coulters extensive experience in ... technology, the CEQ 8000 is a fully ... fills the capillary array with a patented ...
... AquaMax DW4 liquid handling system from Molecular ... all in one instrument. The system handles ... and plate washing96-, 384- and 1536-welland is ... AquaMax DW4 has been optimized to dispense ...
... ProteinPilot Software enables you to ... Now you can distinguish protein isoforms, ... You can also visualize peptide-protein associations ... ideal for protein identification and relative ...
Biology Products: